###begin article-title 0
Signal transducer and activator of transcription 5b: a new target of breast tumor kinase/protein tyrosine kinase 6
###end article-title 0
###begin p 1
This is an open access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Introduction
###end title 2
###begin p 3
Signal transducers and activators of transcription (STATs) are mediators of cytokine and growth factor signaling. In recent years, STAT5b has emerged as a key regulator of tumorigenesis. STAT5b phosphorylation and activation is mediated by several kinases known to be overexpressed in breast cancer, such as epidermal growth factor receptor, HER2, and c-Src. Breast tumor kinase (Brk), also known as protein tyrosine kinase 6, is a nonreceptor tyrosine kinase expressed in more than 60% of breast cancers. Only a few substrates of the Brk tyrosine kinase have been identified, the most recent being STAT3. In the present article we investigate the potential role of Brk in the phosphorylation and activation STAT5b.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 78 87 78 87 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
To determine whether Brk can phosphorylate STAT5b, transient transfection and in vitro kinase assays were performed. Luciferase reporter assays were used to measure Brk-induced STAT5b transcriptional activity. siRNA technology was utilized to investigate the biological significance of Brk-induced activation of STAT5b in breast cancer cell models.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 53 62 53 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
Phosphospecific antibodies, mutational analysis, and in vitro kinase assays demonstrated that Brk specifically mediated STAT5b phosphorylation at the activating tyrosine, Y699. Transient transfection of Brk into the Brk-negative BT-549 breast cancer cell line enhanced STAT5b transcriptional activity, as measured by a STAT5-specific luciferase reporter. Furthermore, overexpression of kinase active c-Src enhanced Brk-induced STAT5b transcriptional activity. In Brk-positive breast cancer cell lines BT-20 and SKBr3, knockdown of Brk protein or of STAT5b protein using siRNA methodology resulted in a decrease in DNA synthesis. Knockdown of Brk and STAT5b together did not further decrease DNA synthesis compared with each alone, suggesting that Brk and STAT5b converge on the same pathway, ultimately leading to cellular proliferation.
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
Our studies demonstrate that Brk phosphorylates STAT5b on Y699, leading to increased STAT5b transcriptional activity. Furthermore, analysis of DNA synthesis suggests that STAT5b and Brk are converging upon the same proproliferative signaling pathway in breast cancer cells. We propose that Brk, like other tyrosine kinases, signals downstream to STAT5b to mediate proliferation of breast cancer cells. These results further establish STAT5b as well as Brk as potential targets for breast cancer therapy.
###end p 9
###begin title 10
Introduction
###end title 10
###begin p 11
###xml 1070 1071 1070 1071 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 1072 1073 1072 1073 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
As mediators of cytokine-induced and growth factor-induced gene expression, signal transducers and activators of transcription (STATs) are involved in cellular differentiation, proliferation, and survival. Upon cytokine or growth factor binding to its receptor, the latent cytoplasmic STAT proteins are recruited to the receptor complex resulting in STAT activation by either receptor tyrosine kinases or nonreceptor tyrosine kinases such as Janus kinases or c-Src. Activation of STAT proteins requires phosphorylation on a conserved tyrosine residue located in the carboxy terminus. Phosphorylation of this tyrosine leads to phosphotyrosine-Src homology domain 2-mediated reciprocal dimerization. The activated STAT dimer then translocates to the nucleus and binds to a STAT consensus DNA element, resulting in gene transcription. The STAT family consists of seven members that can be divided into two categories: those that respond to cytokine signals (STAT2, STAT4, STAT6), and those that respond to cytokine and growth factor signals (STAT1, STAT3, STAT5a, STAT5b) [1-3].
###end p 11
###begin p 12
###xml 215 216 215 216 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 217 218 217 218 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 323 324 323 324 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 328 331 328 331 <italic xmlns:xlink="http://www.w3.org/1999/xlink">myc</italic>
###xml 370 371 370 371 <sub xmlns:xlink="http://www.w3.org/1999/xlink">L</sub>
###xml 450 452 450 452 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 599 601 599 601 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 602 604 602 604 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
Although STAT5a and STAT5b play a fundamental role in normal growth and development of the mammary gland, both proteins are overexpressed or constitutively activated in cancers, including some breast cancer tumors [4-9]. Owing to their ability to regulate the expression of genes involved in cell-cycle regulation (cyclin D1, c-myc, and p21) and cellular survival (Bcl-XL), STAT5a and STAT5b have emerged as possible targets for cancer therapeutics [10]. Recent evidence indicates that STAT5b, but not STAT5a, has a proproliferative role in breast cancer, head and neck cancer, and prostate cancer [11-14]. Since STAT5b mediates breast cancer proliferation, identification of kinases that increase STAT5b activity is critical to identifying potential therapeutic targets.
###end p 12
###begin p 13
###xml 207 209 207 209 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 210 212 210 212 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 318 320 318 320 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 321 323 321 323 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 448 450 448 450 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 451 453 451 453 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 669 671 669 671 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 773 775 773 775 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 873 875 873 875 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 115 122 <span type="species:ncbi:9606">patient</span>
###xml 518 523 <span type="species:ncbi:9606">human</span>
Breast tumor kinase (Brk) is a nonreceptor tyrosine kinase originally isolated from an involved axillary node of a patient with metastatic breast cancer, and is expressed in more than 60% of breast cancers [15,16]. With 46% amino acid identity to c-Src, Brk is distantly related to the Src family of tyrosine kinases [17,18]. Although normally expressed in the gastrointestinal tract, expression of Brk is not detected in the normal mammary gland [16,19]. Stable transfection of Brk in the immortalized nontransformed human mammary cell lines HB4a and MCF10A, however, leads to sensitization to epidermal growth factor and results in a partially transformed phenotype [20]. Brk also enhances epidermal growth factor-induced ErbB3 and Akt phosphorylation in the HB4a cells [21]. Furthermore, knockdown of the Brk protein decreases proliferation of breast cancer cell lines [22]. Given its role in breast cancer cell proliferation, survival, and tumorigenesis, identification of the substrates of this tyrosine kinase is of utmost importance.
###end p 13
###begin p 14
###xml 372 373 372 373 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 374 375 374 375 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
Although STAT5b is involved in cancer proliferation, mutations of STAT5b to account for this increased biological activity have not been identified. Alternatively, increased STAT5b activation results from the overexpression and/or the constitutive activation of tyrosine kinases, such as the epidermal growth factor receptor (EGFR), c-Src, and the fusion protein Bcr/Abl [4,6]. Since all identified Brk substrates are also substrates for c-Src, we examined the ability of Brk to mediate STAT5b phosphorylation, a known c-Src substrate.
###end p 14
###begin p 15
###xml 297 306 297 306 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
In the studies presented here, the ability of Brk to phosphorylate and activate STAT5b and the biological significance of this activation were investigated. Exogenous expression of Brk and STAT5b demonstrated that Brk mediates the phosphorylation of the activating tyrosine, Y699. Furthermore, an in vitro kinase assay determined that Brk can directly phosphorylate STAT5b on Y699. Subsequently, this Brk-mediated STAT5b phosphorylation leads to STAT5b transcriptional activity, and this activity is further increased by kinase active c-Src. The results of siRNA experiments suggest that Brk and STAT5b are in the same signaling pathway, which ultimately leads to the proliferation of breast cancer cells. These studies further support targeting STAT5b as a potential breast cancer therapeutic.
###end p 15
###begin title 16
Materials and methods
###end title 16
###begin title 17
Cell lines and transient transfections
###end title 17
###begin p 18
###xml 262 265 262 265 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 477 479 477 479 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 623 625 623 625 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 4 9 <span type="species:ncbi:9606">human</span>
###xml 232 237 <span type="species:ncbi:10090">Mouse</span>
###xml 290 294 <span type="species:ncbi:10090">mice</span>
###xml 327 335 <span type="species:ncbi:9606">Children</span>
The human breast cancer cell lines SKBr3, BT-20, BT-549, MDA-MB-468, and T47D were obtained from the American Type Culture Collection (Manassas, VA, USA). Cells were maintained in DMEM plus 10% FCS and were passaged twice per week. Mouse embryo fibroblasts (MEF5-/-) from STAT5a/b knockout mice (provided by Dr J Ihle, St Jude Children's Hospital, Memphis, TN, USA) were passaged twice per week and maintained in DMEM plus 10% FCS. Cells were transfected with STAT constructs [23], Brk constructs (generous gift from Dr C Lange, University of Minnesota, Minneapolis, MN, USA), and c-Src constructs as previously described [24], using LipofectAMINE and PLUS reagent according to the manufacturer's instructions (Invitrogen, Gaithersburg, MD, USA).
###end p 18
###begin title 19
Reagents
###end title 19
###begin p 20
###xml 121 123 121 123 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
The polyclonal STAT5a-specific and STAT5b-specific antibodies were developed in our laboratory, as previously described [23]. Polyclonal anti-STAT3 antibodies, polyclonal anti-Brk antibodies, and monoclonal antiphosphotyrosine antibodies (PY-99) were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). The monoclonal anti-beta-actin antibody was from Sigma (St Louis, MO, USA). The antiphospho-STAT5a/b (Y694/Y699) antibody was developed in conjunction with Aves Labs (Tigand, OR, USA) as described elsewhere (EM Fox, T Bernaciak, J Wen, A Weaver, M Shupnik, CM Silva - unpublished data). The protease inhibitor cocktail was from Calbiochem (San Diego, CA, USA). The acrylamide was obtained from Bio-Rad (Hercules, CA, USA), and the prestained molecular weight marker was from Invitrogen. Except as noted, other reagents were of either reagent grade or molecular biological grade from Sigma.
###end p 20
###begin title 21
Immunoprecipitations and immunoblotting
###end title 21
###begin p 22
###xml 586 588 574 576 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
Cells were lysed in 150 mM NaCl, 5 mM ethylenediamine tetraacetic acid, 1% Triton X-100, 1% deoxycholate, 50 mM Tris (pH 7.4), containing protease inhibitors and phosphatase inhibitors. Lysates were incubated with the indicated antibody overnight at 4degreesC, and protein A-agarose (Santa Cruz Biotechnology) was added for an additional 1 hour at 4degreesC. Agarose pellets were washed three times in detergent lysis buffer, and the bound proteins were removed by boiling in 1 x Laemmli buffer. Proteins were separated on polyacrylamide gels and were analyzed as previously described [12].
###end p 22
###begin title 23
Luciferase assay
###end title 23
###begin p 24
###xml 4 8 4 8 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 195 197 195 197 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
MEF5-/- and BT-549 cells were transfected with the Spi2.1-containing luciferase reporter plasmid. Forty-eight hours post transfection, lysates were prepared and luciferase activity was measured [24]. The luciferase values (arbitrary units), as measured by a Berthold Luminometer (Berthold, Oak Ridge, TN, USA), were normalized to total protein.
###end p 24
###begin title 25
Recombinant protein
###end title 25
###begin p 26
###xml 100 103 100 103 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Eco</italic>
###xml 110 113 110 113 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Not</italic>
###xml 214 231 214 231 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Escherichia coli </italic>
###xml 214 235 <span type="species:ncbi:511693">Escherichia coli BL21</span>
STAT5b or Y699F cDNA was cloned into the pGEX4T-1 plasmid (Amersham, Piscataway, NJ, USA) using the EcoRI and NotI restriction sites. The GST, GST-STAT5b, and GST-Y699F plasmids were generated and transformed into Escherichia coli BL21. Protein expression was induced by 1 mM isopropyl-beta-D-thiogalactopyranoside (IPTG in Luria broth (LB) broth at 18degreesC for 18 hours. Bacterial cells were lysed in 1 x PBS containing 1 mM ethylenediamine tetraacetic acid, 5 mM dithiothreitol, 1.5% sarkosyl, 1% Triton, 2 mM phenylmethylsulfonyl fluoride (PMSF), and 1 mug/ml pepstatin followed by sonication. GST, GST-wtSTAT5b, and GST-Y699F were isolated using glutathione agarose beads (Sigma) following the manufacturer's instructions. Following elution with excess glutathione (50 mM Tris-HCl/10 mM glutathione, pH 8.0), the recombinant proteins were dialyzed in 1 x Tris-buffered saline/10% glycerol. Protein concentration was determined by the Bio-Rad Protein Assay (Bio-Rad, Hercules, CA, USA).
###end p 26
###begin title 27
###xml 0 9 0 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink">In vitro </italic>
In vitro kinase assay
###end title 27
###begin p 28
###xml 196 197 196 197 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 209 210 209 210 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 270 271 270 271 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
Purified recombinant Brk (Upstate, Billerica, MA, USA) and purified recombinant GST, GST-STAT5b, or GST-Y699F were incubated with 20 nM ATP in reaction buffer (100 mM Tris-HCl, pH 7.4, 125 mM MgCl2, 25 mM MnCl2, 2 mM ethylene glycol tetraacetic acid (EGTA), 0.25 mM NaVO4, 2 mM dithiothreitol) at 30degreesC for 30 minutes. An equal volume of 2 x Laemmli was added to end the reaction. Phosphorylation of STAT5b was analyzed by immunoblotting with our specific phospho-Y694/Y699 STAT5a/b antibody.
###end p 28
###begin title 29
RNA isolation and reverse transcriptase polymerase chain reaction
###end title 29
###begin p 30
###xml 319 321 316 318 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
Total RNA was isolated from the breast cancer cell lines using the RNeasy mini kit (Qiagen, Valencia, CA, USA) following the manufacturer's instructions. The cDNA was generated using iScript cDNA synthesis (Bio-Rad). The cDNA was amplified using primers for Brk or beta-actin as described by Kasprzycka and colleagues [25].
###end p 30
###begin title 31
Small interfering RNA methodology
###end title 31
###begin p 32
Knockdown of Brk and/or STAT5b was performed using the siGenome SMARTpool duplex (Dharmacon, Lafayette, CO, USA) transfected with Oligofectamine (Invitrogen) according to the manufacturer's instructions.
###end p 32
###begin title 33
DNA synthesis assay
###end title 33
###begin p 34
###xml 255 257 254 256 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 286 290 <span type="species:ncbi:9925">goat</span>
Following 48 hours of transfection with siRNA, SKBr3 cells or BT-20 cells were serum starved for an additional 18 hours and were then incubated with 100 muM bromodeoxyuridine (BrdU) for 6 hours. Cells were fixed and permeabilized as previously described [12]. Cells were blocked in 20% goat serum/PBS for 20 minutes at 37degreesC, and then were incubated with anti-BrdU-Alexa-Fluor 594 (Molecular Probes, Carlsbad, CA, USA) for 1 hour at 37degreesC. BrdU incorporation was visualized using a Leica DM RBE Fluorescence microscope (model RS232C; Leica Microsystems, Bannockburn, IL, USA).
###end p 34
###begin title 35
Results
###end title 35
###begin title 36
STAT tyrosine phosphorylation mediated by breast tumor kinase
###end title 36
###begin p 37
###xml 165 167 165 167 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 168 170 168 170 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 171 173 171 173 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 233 234 233 234 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 413 416 413 416 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 512 516 512 516 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 592 593 592 593 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 355 360 <span type="species:ncbi:10090">Mouse</span>
###xml 403 407 <span type="species:ncbi:10090">mice</span>
Previous studies have demonstrated that STAT5a and STAT5b are tyrosine phosphorylated by the EGFR and c-Src kinases, two kinases that are involved in breast cancer [12,26,27]. Given the recent evidence that Brk phosphorylates STAT3 [1], we investigated whether this kinase could also mediate the phosphorylation of the related STAT5a and STAT5b proteins. Mouse embryo fibroblasts from STAT5a/b knockout mice (MEF5-/-) were transfected with STAT3, STAT5a, or STAT5b along with various Brk expression vectors. MEF5-/- cells were chosen because these cells do not express endogenous Brk (Figure 1), STAT5a, or STAT5b. Immunoprecipitations were performed for the transfected STAT using specific antibodies and were analyzed for tyrosine phosphorylation by immunoblotting. Additionally, total lysates were analyzed for the expression of the Brk constructs.
###end p 37
###begin p 38
###xml 297 300 297 300 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 330 334 330 334 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 341 345 341 345 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 356 360 356 360 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(c) </bold>
###xml 268 273 <span type="species:ncbi:10090">mouse</span>
Breast tumor kinase mediates tyrosine phosphorylation of signal transducers and activators of transcription. Breast tumor kinase (Brk) mediates tyrosine phosphorylation of signal transducer and activator of transcription (STAT)3, STAT5a, and STAT5b. STAT5a/b knockout mouse embryo fibroblast (MEF5-/-) cells were transfected with (a) STAT3, (b) STAT5a, or (c) STAT5b along with either pRc (vector), Brk, K219M Brk (kinase inactive), or Y477F Brk (constitutively active). Immunoprecipitations (IPs) for STAT3, STAT5a, or STAT5b were performed using antibodies specifically directed against each STAT and were analyzed by immunoblotting with antibodies directed toward STAT3, STAT5a, STAT5b (middle), or phosphotyrosine (top). Total lysates were analyzed for the expression of the Brk construct by immunoblotting with anti-Brk antibody (bottom).
###end p 38
###begin p 39
###xml 44 46 44 46 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1a</xref>
###xml 276 277 276 277 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 416 420 416 420 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1b,c</xref>
###xml 678 680 678 680 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 774 776 774 776 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
In agreement with previous findings, Figure 1a demonstrates that wildtype Brk and constitutively active Brk (Y447F) were able to mediate STAT3 tyrosine phosphorylation, while the kinase inactive Brk (K219M) or vector (pRc) demonstrated no detectable tyrosine phosphorylation [1]. Importantly, Brk and the Y447F Brk, but not the K219M Brk, were also able to mediate STAT5a and STAT5b tyrosine phosphorylation (Figure 1b,c). These data demonstrate for the first time that Brk mediates tyrosine phosphorylation of STAT5a and STAT5b in addition to STAT3. Since our previous studies demonstrated that STAT5b, but not STAT5a, elicits a proproliferative effect in breast cancer cells [12], and other studies have shown that Brk also increases proliferation of breast cancer cells [22], we focused our efforts on Brk-mediated activation of STAT5b.
###end p 39
###begin title 40
Phosphorylation of STAT5b by breast tumor kinase
###end title 40
###begin p 41
###xml 183 185 183 185 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 398 400 398 400 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 401 403 401 403 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 560 564 560 564 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
While phosphorylation of Y699 is required for transcriptional activity, three tyrosines located in the transactivation domain can also be phosphorylated and modulate STAT5b activity [23]. These tyrosines are either positive (Y725) or negative (Y740 and Y743) regulators of STAT5b activity, and their phosphorylations are mediated by c-Src (Y699 and Y725) and the EGFR (Y699, Y725, Y740, and Y743) [12,27]. We investigated the ability of Brk to phosphorylate each of the four identified tyrosine sites, starting with the required activating tyrosine, Y699. MEF5-/- cells were transfected with STAT5b along with Brk constructs, and STAT5b immunoprecipitations were analyzed using the antiphospho-Y699 STAT5b-specific antibody.
###end p 41
###begin p 42
###xml 156 158 156 158 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2a</xref>
###xml 249 253 249 253 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 639 641 639 641 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2b</xref>
Both Brk and Y447F Brk were able to mediate the phosphorylation of Y699, while it was not detectable in vector cells or K219M Brk-transfected cells (Figure 2a). To determine whether Brk mediates the phosphorylation of tyrosines other than Y699, MEF5-/- cells were transfected with Brk along with STAT5b mutants in which all but one of the four tyrosines was mutated. Brk induced detectable tyrosine phosphorylation of wildtype STAT5b and the Y725/740/743F mutant (with intact Y699), confirming the results with the antiphospho-Y699-specific antibody. None of the other STAT5b mutant constructs, however, were phosphorylated by Brk (Figure 2b). These results demonstrate that Brk primarily mediates Y699 phosphorylation on STAT5b and not the three transactivation domain tyrosines.
###end p 42
###begin p 43
###xml 109 113 109 113 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 142 145 142 145 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 506 510 506 510 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 514 518 514 518 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 778 782 778 782 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(c) </bold>
###xml 786 790 786 790 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 1301 1303 1287 1289 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t </italic>
###xml 1391 1393 1377 1379 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 113 118 <span type="species:ncbi:10090">Mouse</span>
Signal transducer and activator of transcription 5b tyrosine phosphorylation and transcriptional activation. (a) Mouse embryo fibroblast (MEF5-/-) cells were transfected with signal transducer and activator of transcription 5b (STAT5b) along with pRc (vector), breast tumor kinase (Brk), K219M, or Y447F. Immunoprecipitations (IPs) were performed using antibodies specifically against STAT5b and were analyzed by immunoblotting with antibodies directed toward phospho-Y699 STAT5b (top) or STAT5b (bottom). (b) MEF5-/- cells were transfected with various STAT5b constructs along with constitutively active Y447F Brk. Immunoprecipitations (IPs) were performed as above and were analyzed via immunoblotting with antiphosphotyrosine antibody (top) or anti-STAT5b antibody (bottom). (c) MEF5-/- were transfected with the STAT5-specific Spi2.1 promoter luciferase construct and either His-vector, His-STAT5b, or His-Y699F with or without Brk. Luciferase activity was measured and normalized to total protein. Values from four independent experiments performed in triplicate reported as the fold induction over His, pRc +/- standard error: His, pRc (1.00 +/- 0.00) and Brk (1.05 +/- 0.39); STAT5b, pRc (28.89 +/- 5.51) and Brk (75.48 +/- 25.79); Y699F, pRc (1.17 +/- 0.14) and Brk (0.93 +/- 0.27). Student's t test was used to determine statistical significance between STAT5b pRc and STAT5b Brk. *P = 0.0123.
###end p 43
###begin title 44
Breast tumor kinase mediates STAT5b transcriptional activity
###end title 44
###begin p 45
###xml 162 166 162 166 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 327 331 327 331 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 497 499 497 499 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2c</xref>
Since Y699 phosphorylation is required for the transcriptional function of STAT5b, we analyzed the ability of Brk to mediate STAT5b transcriptional activity. MEF5-/- cells were transfected with the STAT5-specific luciferase reporter plasmid (Spi2.1-luc) along with His-vector, STAT5b, or Y699F plus or minus Brk. Since the MEF5-/- cells express endogenous STAT1 and STAT3, the specificity of this reporter was demonstrated by the inability of the His-vector to mediate luciferase activity (Figure 2c). The expression of STAT5b increased Spi2.1-mediated luciferase activity, and the cotransfection of Brk significantly increased this transcriptional activity further. As seen previously, the Y699F STAT5b mutant was unable to mediate STAT5b transcriptional activity, and the addition of Brk had no effect. These results demonstrate not only that Brk mediates STAT5b transcriptional activity, but that Y699 is required.
###end p 45
###begin title 46
###xml 59 67 59 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
Breast tumor kinase directly phosphorylates Y699 of STAT5b in vitro
###end title 46
###begin p 47
###xml 196 205 196 205 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 333 342 333 342 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 396 398 396 398 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3a</xref>
###xml 481 483 481 483 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3b</xref>
###xml 583 585 583 585 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3a</xref>
###xml 739 741 739 741 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3b</xref>
###xml 1055 1063 1055 1063 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
To determine whether Brk could mediate the phosphorylation and activation of STAT5b directly, or whether other tyrosine kinases known to activate STAT5b (such as EGFR and c-Src) were required, an in vitro kinase assay was performed. Purified recombinant Brk was incubated with purified recombinant GST, GST-STAT5b, or GST-Y699F. The in vitro kinase reaction was analyzed via silver stain (Figure 3a) and by immunoblotting with the antiphospho-Y699 STAT5b-specific antibody (Figure 3b). The silver stain illustrates that GST, GST-STAT5b, GST-Y699F, and Brk were all expressed (Figure 3a). Furthermore, the specificity of the phospho-Y699 STAT5b antibody was confirmed by its inability to recognize the recombinant GST-Y699F protein (Figure 3b). Phospho-Y699 STAT5b antibody, however, detected phosphorylated Brk in this assay. Immunoblotting with this antibody demonstrated that the GST-STAT5b was phosphorylated on Y699 in the presence of, but not in the absence of, Brk. This result demonstrates that Brk is able to directly phosphorylate Y699 on STAT5b in vitro.
###end p 47
###begin p 48
###xml 0 9 0 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink">In vitro </italic>
###xml 0 52 0 52 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>In vitro </italic>Y699 phosphorylation by breast tumor kinase</bold>
###xml 54 63 54 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink">In vitro </italic>
###xml 492 496 486 490 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 513 517 507 511 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
In vitro Y699 phosphorylation by breast tumor kinase. In vitro Y699 phosphorylation of signal transducer and activator of transcription 5b (STAT5b) by breast tumor kinase (Brk). Purified recombinant GST, GST-STAT5b, or GST-Y699F were incubated with (+) or without (-) purified recombinant Brk in reaction buffer containing 20 nM ATP at 30degreesC for 30 minutes. An equal volume of 2 x Laemmli buffer was added to end the reaction and the samples were run on SDS-PAGE. Gels were analyzed via (a) silver stain and (b) by immunoblotting with an antiphospho-Y699 STAT5b-specific antibody.
###end p 48
###begin title 49
###xml 34 39 <span type="species:ncbi:9606">human</span>
Breast tumor kinase expression in human breast cancer cell lines
###end title 49
###begin p 50
###xml 25 29 25 29 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 528 530 525 527 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 720 722 714 716 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4a</xref>
While studies in the MEF5-/- cells allowed us to characterize the role of Brk in STAT5b activation, we continued our studies in breast cancer cell lines as a means to investigate the biological relevance of Brk-mediated STAT5b activation. We determined the relative expression of Brk by analyzing mRNA and protein levels in a panel of frequently studied breast cancer cell lines. The total mRNA was isolated from each cell line, cDNA was generated, and primers specific for either Brk or beta-actin were used for amplification [25]. In each sample, the relative expression of Brk mRNA was determined by normalizing to the amount of beta-actin. The expression of Brk mRNA in the MDA-MB-468 cell line was set to 1 (Figure 4a) because this cell line expressed the lowest detectable amount of Brk mRNA. While BT-20 cells and T47D cells had the highest mRNA levels, SKBr3 cells and MDA-MB-468 cells expressed moderate levels, and BT-549 cells had no detectable Brk mRNA.
###end p 50
###begin p 51
###xml 60 64 60 64 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 565 569 559 563 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
Breast tumor kinase expression in breast cancer cell lines. (a) Total RNA was isolated from the breast cancer cell lines using the RNeasy kit (Qiagen), and the cDNA was generated using iScript cDNA synthesis (Bio-Rad). The cDNA was amplified using primers specifically for breast tumor kinase (Brk) or beta-actin. The relative level of Brk mRNA was determined using densitometric analysis and was normalized to the amount of beta-actin. The level of Brk mRNA in the MDA-MB-468 cell line was set to 1; numbers indicate the fold increase compared with the 468 cells. (b) Whole-cell lysates were prepared from the breast cancer cell lines. Lysates were immunoblotted with anti-Brk antibody (top) and with anti-Ran antibody (bottom). The relative expression of Brk protein was determined using densitometric analysis and was normalized to the amount of Ran. The expression of Brk protein in the MDA-MB-468 cell line was set to 1; numbers indicate the fold increase compared with the 468 cells.
###end p 51
###begin p 52
###xml 289 291 289 291 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 375 377 375 377 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4b</xref>
The amount of Brk protein in detergent cell lysates from each cell line was determined by immunoblotting. The relative expression of Brk protein was determined by normalizing to the nuclear import protein Ran, shown previously as a valid normalization control in breast cancer cell lines [28]. Again the amount of Brk protein in the MDA-MB-468 cell line was set to 1 (Figure 4b) because this cell line had the lowest detectable amount of Brk protein. Brk was highly expressed in BT-20 cells and T47D cells, was moderately expressed in SKBr3 cells and MDA-MB-468 cells, and was not detectable in BT-549 cells. Relatively high levels of Brk expression were seen in both the estrogen-receptor-positive T47D cells and the estrogen-receptor-negative BT-20 cells. Furthermore, while MDA-MB-468 cells, BT-20 cells, and BT-549 cells all express the EGFR, they expressed different amounts of Brk.
###end p 52
###begin title 53
Breast tumor kinase mediates STAT5b activity in breast cancer cells
###end title 53
###begin p 54
###xml 495 497 495 497 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5a</xref>
To examine the ability of Brk to mediate the transcriptional activity of endogenous STAT5b in a breast cancer cell line, the BT-549 cells, which have no detectable endogenous Brk, were utilized. The STAT5-specific Spi2.1 luciferase reporter with or without Brk was transfected into the BT-549 cells. While there was a detectable basal level of transcriptional activity, Brk significantly increased endogenous STAT5b transcriptional activity, as did the constitutively active Brk (Y447F) (Figure 5a). Although not nearly as effective, the kinase inactive Brk (K219M) did significantly increase the STAT5b luciferase activity compared with vector alone. This result is not necessarily unexpected since a role of the kinase inactive Brk in other cell models has been reported (see Discussion).
###end p 54
###begin p 55
###xml 118 122 118 122 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 602 604 592 594 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t </italic>
###xml 705 707 695 697 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 719 721 709 711 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 731 735 721 725 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 1311 1313 1283 1285 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t </italic>
###xml 1469 1471 1441 1443 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1483 1485 1455 1457 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1497 1499 1469 1471 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
Breast tumor kinase mediates endogenous signal transducer and activator of transcription 5b transcriptional activity. (a) BT-549 cells were transfected with the Spi2.1 promoter luciferase construct along with pRc, breast tumor kinase (Brk), K219M, or Y447F expression vectors. Luciferase activity was measured and normalized to total protein. Values from four independent experiments carried out in triplicate were reported as average luciferase/protein +/- standard error: pRc (1,859.37 +/- 592.24); Brk (10,031.94 +/- 1,359.68); K219M (3,109.82 +/- 777.57), Y477F (12,878.57 +/- 2,464.26). Student's t test was used to determine statistical significance between pRc and Brk, and between pRc and K219M. *P < 0.0001, * P = 0.0430. (b) BT-549 cells were transfected with the Spi2.1 promoter luciferase construct along with pRc, Brk, or K219M, and either pcDNA, c-Src, or K-Src expression vectors. Luciferase activity was measured and normalized to total protein. Values from four independent experiments carried out in triplicate were reported as the average fold induction over pcDNA, pRc +/- SE: pcDNA, pRc (1.00 +/- 0.00), Brk (2.92 +/- 0.39), and K219M (1.36 +/- 0.13); c-Src, pRc (1.10 +/- 0.12), Brk (5.01 +/- 0.38), and K219M (1.24 +/- 0.18); K-Src, pRc (0.99 +/- 0.19) and Brk (2.76 +/- 0.89). Student's t test was used to determine statistical significance between pcDNA pRc and pcDNA Brk, between pcDNA pRc and pcDNA K219M, and between pRc Brk and c-Src Brk. *P = 0.0027, * P = 0.0322, â—† P < 0.0086.
###end p 55
###begin p 56
###xml 286 288 286 288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5b</xref>
###xml 395 397 395 397 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5b</xref>
Since Brk and c-Src are both able to phosphorylate STAT5b on Y699, the potential cooperation between Brk and c-Src was investigated. As previously, Brk dramatically enhanced STAT5b transcriptional activity, and the K219M Brk was also able to significantly enhance this activity (Figure 5b). Unexpectedly, exogenous overexpression of c-Src did not enhance STAT5b transcriptional activity (Figure 5b). c-Src overexpression enhanced Brk-induced STAT5b transcriptional activity, however, indicating that Brk and c-Src together can enhance STAT5b transcriptional activity. The kinase activity of Brk was necessary for this collaboration as the addition of c-Src to K219M Brk did not enhance STAT5b activity. Likewise, the kinase inactive c-Src (K-Src) failed to significantly enhance Brk-induced STAT5b transcriptional activity, suggesting that the kinase activity of c-Src is also necessary for this cooperation between Brk and c-Src. While Brk and c-Src individually have different effects on STAT5b transcriptional activity, these two tyrosine kinases together increase STAT5b transcriptional activity. These data suggest that Brk and c-Src do not merely substitute for one another in activating STAT5b, but rather that Brk can function independently as well as together with c-Src.
###end p 56
###begin title 57
STAT5b and breast tumor kinase involvement in DNA synthesis
###end title 57
###begin p 58
###xml 250 252 250 252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 253 255 253 255 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 256 258 256 258 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 259 261 259 261 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 273 275 273 275 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
To determine the biological significance of the Brk-mediated increase in STAT5b activity, the role of Brk and STAT5b, individually and together, on DNA synthesis in breast cancer cell lines was investigated. Since Brk signals downstream of the EGFR [20,21,30,30] and HER2 [29] tyrosine kinases, the EGFR/HER2-overexpressing SKBr3 breast cancer cell line and the EGFR-overexpressing BT-20 breast cancer cell line were chosen for these studies. Both cell lines express the c-Src and Brk tyrosine kinases as well as STAT5b. To investigate the effect on proliferation, siRNA technology was used to knockdown Brk or STAT5b protein levels, individually or together, and then the effect on DNA synthesis was measured by BrdU incorporation. Lysates were analyzed via immunoblotting to determine significant and specific knockdown of Brk and STAT5b.
###end p 58
###begin p 59
###xml 19 23 19 23 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6a,c</xref>
###xml 396 400 396 400 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6b,d</xref>
As shown in Figure 6a,c, knockdown of Brk did not effect the expression of STAT5b and knockdown of STAT5b did not effect the expression of Brk. Furthermore, knockdown of Brk and/or STAT5b did not effect the expression of HER2, EGFR, c-Src, STAT3, or STAT1 (data not shown). Knockdown of Brk (siBrk) inhibited DNA synthesis in both SKBr3 cells and BT-20 cells by 47% and 31%, respectively (Figure 6b,d). Knockdown of STAT5b (siSTAT5b) significantly decreased DNA synthesis of both cell lines to an extent similar to that seen with Brk knockdown. Importantly, the knockdown of Brk and STAT5b together did not further decrease DNA synthesis compared with either single knockdown, suggesting that signaling mediated by Brk and STAT5b are contributing to the same proproliferative pathway.
###end p 59
###begin p 60
###xml 0 98 0 98 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Breast tumor kinase and signal transducer and activator of transcription 5b roles in DNA synthesis</bold>
###xml 222 229 222 229 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a, b) </bold>
###xml 244 251 244 251 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(c, d) </bold>
###xml 1172 1174 1157 1159 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t </italic>
###xml 1343 1345 1328 1330 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1359 1361 1342 1344 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1657 1659 1628 1630 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t </italic>
###xml 1828 1830 1799 1801 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1844 1846 1813 1815 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
Breast tumor kinase and signal transducer and activator of transcription 5b roles in DNA synthesis. Knockdown of breast tumor kinase (Brk) and/or signal transducer and activator of transcription 5b (STAT5b) in SKBr3 cells (a, b) or BT-20 cells (c, d) was performed using the Dharmacon siGenome SMARTpool duplex for each protein as per the manufacturer's instructions. (a, c) Seventy-two hours after transfection of the siRNA, cells were lysed. Total lysates were analyzed via immunoblotting with anti-STAT5b (top), anti-Brk (middle), or anti-beta-actin (bottom) antibodies. (b, d) Sixty-six hours after transfection of the siRNA, bromodeoxyuridine (BrdU) was added to the medium for 6 hours. The cells were fixed and stained with a fluorescent antibody against BrdU. Cells were scored for BrdU incorporation and graphed. Between 160 and 200 cells were counted for each treatment group. (b) Average percentage of BrdU incorporation +/- standard error from three independent experiments performed in triplicate for the SKBr3 cells: media (21.54 +/- 0.16), siLuc (24.98 +/- 2.78), siBrk (12.37 +/- 1.65), siSTAT5b (12.37 +/- 0.51), siBrk/siSTAT5b (12.39 +/- 0.21). Student's t test was utilized to determine statistical significance between media and siBrk, siSTAT5b, or siBrk/siSTAT5b, and between siLuc and siBrk, siSTAT5b, or siBrk/siSTAT5b. *P </= 0.0050, * P < 0.0025. (d) Average percentage of BrdU incorporation +/- standard error from three independent experiments performed in triplicate for the BT-20 cells: media (25.28 +/- 0.55), siLuc (26.87 +/- 0.52), siBrk (18.97 +/- 0.32), siSTAT5b (18.87 +/- 0.03), siBrk/siSTAT5b (17.37 +/- 0.88). Student's t test was utilized to determine statistical significance between media and siBrk, siSTAT5b, or siBrk/siSTAT5b, and between siLuc and siBrk, siSTAT5b, or siBrk/siSTAT5b. *P </= 0.0016, * P < 0.0007.
###end p 60
###begin title 61
Discussion
###end title 61
###begin p 62
###xml 383 385 383 385 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 394 396 394 396 <sub xmlns:xlink="http://www.w3.org/1999/xlink">L </sub>
###xml 397 399 397 399 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 400 402 400 402 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 502 504 502 504 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 505 507 505 507 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 617 618 617 618 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6</xref>
###xml 621 623 621 623 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 747 749 747 749 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
Although traditionally known for its role in growth hormone signaling and mammary gland development, STAT5b has emerged as a therapeutic target due to its pivotal role in cancer. Inhibition of STAT5b, but not of STAT5a, in xenograft models of head and neck carcinomas via antisense oligonucleotides repressed tumor growth and hindered expression of the STAT5-regulated genes cyclin D1 and Bcl-XL [13,14]. STAT5b is more abundantly expressed than STAT5a in prostate cancer and breast cancer cell lines [12,31]. Inhibition of STAT5b via dominant-negative constructs and siRNA technology decreases DNA synthesis (Figure 6) [32], while exogenous expression of a basally active STAT5b mutant (Y740/743F) increases DNA synthesis of breast cancer cells [12]. Together, these data establish a fundamental role for STAT5b in the process of breast cancer tumorigenesis.
###end p 62
###begin p 63
###xml 444 445 444 445 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
Since activating mutations in STAT5b have not been found in breast cancer, it is important to look upstream to identify the kinases that regulate STAT5b, thus potentially leading to its increased activity in breast cancer cells. Both STAT5b and STAT3 are activated by several kinases overexpressed in breast cancer, including the EGFR, HER2, and c-Src. STAT3 was recently shown to also be phosphorylated by the nonreceptor tyrosine kinase Brk [1]. Since Brk is expressed in more than 60% of breast tumors but not in normal mammary tissue, it has been suggested to be a potential therapeutic target for breast cancer. Since evidence supports the involvement of both Brk and STAT5b in breast cancer proliferation, we investigated the ability of Brk to phosphorylate STAT5b and the biological significance of this activation.
###end p 63
###begin p 64
###xml 205 207 205 207 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 365 366 365 366 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 367 369 367 369 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 370 372 370 372 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 373 375 373 375 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 481 482 481 482 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 621 623 621 623 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2b</xref>
###xml 626 628 626 628 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 629 631 629 631 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 750 751 750 751 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 839 848 839 848 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 1087 1096 1087 1096 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
Using synthetic peptides containing consensus motifs for the EGFR, insulin receptor, c-Src, or Abl tyrosine kinases, it was determined that the c-Src-preferred synthetic peptide is the best Brk substrate [17]. Given these data, it is not surprising that all of the identified Brk substrates (Sam68, SLM-1, SLM-2, STAP-2, paxillin, STAT3) are also c-Src substrates [1,30,33-35]. We have identified two more Brk substrates, STAT5a and STAT5b, which are also c-Src substrates (Figure 1). c-Src can mediate the phosphorylation of Y699 and Y725, however, Brk mediates Y699 phosphorylation but not Y725 phosphorylation (Figure 2b) [12,27]. A previous study demonstrated that Brk mediated phosphorylation of STAT3, but not of STAT1, STAT2, STAT5, or STAT6 [1]. These studies were performed in COS1 cells, however, not in breast cancer cells, and in vitro kinase assays were not performed for STATs other than STAT3. Using our previously characterized STAT5b-specific antibodies, we demonstrated here that Brk can also directly phosphorylate Y699 on STAT5b in breast cancer cell lines and in an in vitro kinase assay.
###end p 64
###begin p 65
###xml 536 538 536 538 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 1337 1339 1337 1339 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 1340 1342 1340 1342 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 1466 1468 1466 1468 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
Exogenous expression of Brk in the Brk-negative breast cancer cell line BT-549 increased endogenous STAT5b transcriptional activity. Interestingly, the catalytically inactive K219M Brk mutant also significantly increased STAT5b transcriptional activity compared with vector alone, although not to the extent seen with wildtype Brk or the constitutively active (Y447F). In fact, Harvey and Crompton have previously reported that the kinase-inactive Brk mutant (K219M) could increase the proliferation of T47D cells compared with vector [22]. Since the K219M mutation disrupts the ATP-binding motif, but not the Src homology domain 2 or the Src homology domain 3, these data suggest that Brk has a role in intracellular signaling that does not require its kinase activity. In these cases, Brk may function as an adaptor protein. Finally, although the constitutively active Y447F Brk mutant was able to increase STAT5b transcriptional activity, it was not significantly higher than that seen with wildtype Brk. This mutation is at the presumptive autoinhibitory tyrosine phosphorylation site of Brk (Y447), equivalent to that identified in c-Src (Y527). Although the Y447F Brk increases phosphorylation of a synthetic peptide, the autophosphorylation of the activating tyrosine in Brk (Y342) is comparable with that seen with wildtype Brk [17,36]. Nevertheless, the Y447F Brk mutant has decreased transforming potential when compared with wildtype Brk in NIH3T3 cells [20]. Together, these data as well as the results we have presented here suggest that the regulation of Brk is more complex than originally thought, and probably involves its role as a kinase and an adaptor protein depending on the cell context.
###end p 65
###begin p 66
###xml 278 280 278 280 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5b</xref>
###xml 458 460 458 460 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
Since both c-Src and Brk tyrosine kinases are frequently overexpressed in breast cancer and since they both mediate Y699 phosphorylation of STAT5b, there is potential for these kinases to either substitute for one another or work together to activate STAT5b. As shown in Figure 5b, exogenous overexpression of c-Src, unlike Brk, did not enhance STAT5b transcriptional activity in the BT-549 cells, although we have reported that it does in other cell lines [12]. Exogenous expression of c-Src along with Brk, however, enhanced STAT5b transcriptional activity to a level greater than that with Brk alone. As the kinase-inactive c-Src did not enhance Brk-mediated STAT5b transcriptional activity, c-Src kinase activity may play a role in increasing the phosphorylation and functional activation of Brk. Together, these results demonstrate that c-Src and Brk do not merely substitute for one another in mediating STAT5b transcriptional activation. Rather, Brk can function independently of c-Src, or these two kinases can work together to enhance STAT5b activity.
###end p 66
###begin p 67
###xml 202 204 202 204 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 455 457 455 457 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 695 697 687 689 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 861 863 853 855 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 864 866 856 858 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 1009 1011 1001 1003 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 1078 1080 1070 1072 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 711 716 <span type="species:ncbi:9606">human</span>
While Brk is not expressed in normal mammary epithelial cells, it is expressed in 60% of breast tumors - suggesting that Brk expression is regulated at the transcriptional level in breast cancer cells [16]. Furthermore, the DNA sequence of Brk isolated from gastrointestinal epithelial cells and that of Brk isolated from breast tumor cells are identical, suggesting that activating mutations in Brk are not accountable for Brk activity in breast cancer [18]. Located within the minimal functional promoter of Brk are NF-kappaB, Sp1, and STAT consensus binding sites, all known to play a role in tumorigenesis. Only NF-kappaB and Sp1, however, have thus far been shown to bind the Brk promoter [37]. Reports in human breast cancer samples have varied, showing that Brk correlates with HER2 and HER4 overexpression, as well as with estrogen receptor positivity [38-40]. There is also conflicting evidence showing a strong correlation between Brk staining by immunohistochemistry and tumor grade in one report [29], and another correlating Brk expression with long-term survival [39].
###end p 67
###begin p 68
###xml 185 186 185 186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
###xml 375 376 375 376 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6</xref>
###xml 931 933 931 933 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 1040 1042 1040 1042 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 1077 1079 1077 1079 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 1121 1123 1121 1123 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 48 53 <span type="species:ncbi:9606">human</span>
Our mRNA and protein analysis across a panel of human breast cancer cell lines showed no correlation of Brk expression with estrogen receptor status or EGFR/HER2 overexpression (Figure 4). We have, however, shown that knockdown of Brk significantly decreased DNA synthesis in the EGFR-overexpressing and c-Src-overexpressing breast cancer cell lines, SKBr3 and BT-20 (Figure 6). The effect of Brk knockdown on inhibiting basal DNA synthesis was comparable with that seen with STAT5b knockdown in both cell lines. Furthermore, simultaneous knockdown of both Brk and STAT5b had the same effect on decreasing DNA synthesis as their individual knockdowns, suggesting that this kinase and substrate converge upon a pathway ultimately leading to proliferation. Ostander and colleagues have shown that Brk knockdown decreases cell growth as well as epidermal growth factor-induced (or heregulin-induced) migration of breast cancer cells [29]. Additionally, knockdown of Brk decreases epidermal growth factor-induced (or heregulin-induced) cyclin D1 expression in breast cancer cells [29]. As STAT5b is known to regulate cyclin D1 through consensus sites in the promoter, this pathway may be one mechanism by which Brk and STAT5b together regulate increases in DNA synthesis. Given the evidence that we have provided for the functionally relevant regulation of STAT5b by Brk, further pursuing the role of this Brk-STAT5b pathway in breast cancer may provide important novel therapeutic targets.
###end p 68
###begin title 69
Conclusion
###end title 69
###begin p 70
We have demonstrated that the nonreceptor tyrosine kinase Brk positively regulates STAT5b activity leading to proliferation of breast cancer cells. Based on our studies, we propose that HER2, EGFR, c-Src, and Brk all signal downstream to STAT5b to increase proliferation of breast cancer cells. We hypothesize that inhibition of STAT5b would obstruct the proliferative signal that is transmitted via these kinases resulting in decreased tumor growth.
###end p 70
###begin title 71
Abbreviations
###end title 71
###begin p 72
###xml 149 153 <span type="species:ncbi:9913">calf</span>
BrdU = bromodeoxyuridine; Brk = breast tumor kinase; DMEM = Dulbecco's modified Eagle's medium; EGFR = epidermal growth factor receptor; FCS = fetal calf serum; NF = nuclear factor; PBS = phosphate-buffered saline; siRNA = small interfering RNA; STAT = signal transducer and activator of transcription.
###end p 72
###begin title 73
Competing interests
###end title 73
###begin p 74
The authors declare that they have no competing interests.
###end p 74
###begin title 75
Authors' contributions
###end title 75
###begin p 76
AMW performed all the experiments. Both AMW and CMS conceived the experiments, analyzed the data, and drafted the manuscript. Both authors read and approved the final manuscript.
###end p 76
###begin title 77
Acknowledgements
###end title 77
###begin p 78
###xml 52 57 <span type="species:ncbi:9606">Women</span>
This study was supported by RO1-CA085462 and by the Women's Oncology Program of the UVA Cancer Center. The authors thank Dr Carol Lange for the generous gift of the Brk constructs, and Brian Del Rosario for his help in recombinant protein production. They appreciate the expert technical assistance of Elise M Branch. The authors thank Teresa M Bernaciak and the research group of Dr Sarah J Parsons for insightful comments.
###end p 78
###begin article-title 79
Identification of STAT3 as a specific substrate of breast tumor kinase
###end article-title 79
###begin article-title 80
STATs: transcriptional control and biological impact
###end article-title 80
###begin article-title 81
STAT proteins and transcriptional responses to extracellular signals
###end article-title 81
###begin article-title 82
STATs in oncogenesis
###end article-title 82
###begin article-title 83
Transcription factors as targets for cancer therapy
###end article-title 83
###begin article-title 84
The STATs of cancer - new molecular targets come of age
###end article-title 84
###begin article-title 85
Activation of Stat5a and Stat5b by tyrosine phosphorylation is tightly linked to mammary gland differentiation
###end article-title 85
###begin article-title 86
Signal transducers and activators of transcription as regulators of growth, apoptosis and breast development
###end article-title 86
###begin article-title 87
Role of STATs as downstream signal transducers in Src family kinase-mediated tumorigenesis
###end article-title 87
###begin article-title 88
###xml 28 33 <span type="species:ncbi:9606">human</span>
Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention
###end article-title 88
###begin article-title 89
###xml 75 80 <span type="species:ncbi:9606">human</span>
STAT5 promotes homotypic adhesion and inhibits invasive characteristics of human breast cancer cells
###end article-title 89
###begin article-title 90
Modulation of signal transducer and activator of transcription 5b activity in breast cancer cells by mutation of tyrosines within the transactivation domain
###end article-title 90
###begin article-title 91
Src kinases mediate STAT growth pathways in squamous cell carcinoma of the head and neck
###end article-title 91
###begin article-title 92
Constitutive activation of Stat5b contributes to carcinogenesis in vivo
###end article-title 92
###begin article-title 93
###xml 85 88 85 88 <italic xmlns:xlink="http://www.w3.org/1999/xlink">brk</italic>
###xml 103 108 <span type="species:ncbi:9606">human</span>
Cloning and characterization of cDNAs encoding a novel non-receptor tyrosine kinase, brk, expressed in human breast tumors
###end article-title 93
###begin article-title 94
###xml 55 60 <span type="species:ncbi:9606">human</span>
BRK tyrosine kinase expression in a high proportion of human breast carcinomas
###end article-title 94
###begin article-title 95
Regulation of the nonreceptor tyrosine kinase Brk by autophosphorylation and by autoinhibition
###end article-title 95
###begin article-title 96
Brk, Srm, Frk, and Src42A from a distinct family of intracellular Src-like tyrosine kinases
###end article-title 96
###begin article-title 97
BRK/Sik expression in the gastrointestinal tract and in colon tumors
###end article-title 97
###begin article-title 98
Brk, a breast tumor-derived non-receptor protein-tyrosine kinase, sensitizes mammary epithelial cells to epidermal growth factor
###end article-title 98
###begin article-title 99
Expression of BRK tyrosine kinase in mammary epithelial cells enhance the coupling of EGF signalling to PI-3 kinase and Akt, via erbB3 phosphorylation
###end article-title 99
###begin article-title 100
Use of RNA interference to validate Brk as a novel therapeutic target in breast cancer: Brk promotes breast cancer carcinoma cell proliferation
###end article-title 100
###begin article-title 101
Novel activation of STAT5b in response to epidermal growth factor
###end article-title 101
###begin article-title 102
STAT5b, a mediator of synergism between c-Src and the epidermal growth factor receptor
###end article-title 102
###begin article-title 103
Expression and oncogenic role of Brk (PTK6/Sik) protein tyrosine kinase in lymphocytes
###end article-title 103
###begin article-title 104
ErbB receptor-induced activation of Stat transcription factors is mediated by Src tyrsoine kinases
###end article-title 104
###begin article-title 105
Signal transduction pathways regulated by prolactin and Src result in different conformations of activated Stat5b
###end article-title 105
###begin article-title 106
Extracellular signal-regulated kinase 7, a regulator of hormone-dependent estrogen receptor destruction
###end article-title 106
###begin article-title 107
Breast tumor kinase (protein tyrosine kinase 6) regulates heregulin-induced activation of ERK5 and p38 MAP kinases in breast cancer cells
###end article-title 107
###begin article-title 108
Brk activates Rac1 and promotes cell migration and invasion by phosphorylating paxillin
###end article-title 108
###begin article-title 109
###xml 61 66 <span type="species:ncbi:9606">human</span>
Erythropoietin stimulates growth and STAT phosphorylation in human prostate epithelial and prostate cancer cells
###end article-title 109
###begin article-title 110
###xml 133 138 <span type="species:ncbi:9606">human</span>
Estrogen negatively regulates epidermal growth factor (EGF)-mediated signal transducer and activator of transcription 5 signaling in human EGF family receptor-overexpressing breast cancer cells
###end article-title 110
###begin article-title 111
Tyrosine phosphorylation of Sam68 by breast tumor kinase regulates intranuclear localization and cell cycle progression
###end article-title 111
###begin article-title 112
The nuclear tyrosine kinase BRK/Sik phosphorylates and inhibits the RNA-binding activities of the Sam68-like mammalian proteins SLM-1 and SLM-2
###end article-title 112
###begin article-title 113
A novel adaptor-like protein which is a substrate for the non-receptor tyrosine kinase, BRK
###end article-title 113
###begin article-title 114
Solution structure and backbone dynamics of the non-receptor protein-tyrosine kinase 6 src homology 2 domain
###end article-title 114
###begin article-title 115
###xml 56 61 56 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTK6 </italic>
###xml 50 55 <span type="species:ncbi:9606">human</span>
Characterization of the 5'-flanking region of the human PTK6 gene
###end article-title 115
###begin article-title 116
###xml 36 45 36 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Her2/neu </italic>
Simultaneous over-expression of the Her2/neu and PTK6 tyrosine kinase in archival invasive ductal breast carcinomas
###end article-title 116
###begin article-title 117
PTK (protein tyrosine kinase)-6 and HER2 and 4, but not HER1 and 3 predict long-term survival in breast carcinomas
###end article-title 117
###begin article-title 118
Elevated expression levels of NCOA3, TOP1, and TFAP2C in breast tumors as predictors of poor prognosis
###end article-title 118

